Objective-Adenosine monophosphate activated protein kinase (AMPK) has been identified as a regulator of vascular function via the preservation of endothelial cell (EC) function. In this study, we examined whether the beneficial effects of AMPK on ECs are dependent on its involvement in cholesterol efflux and its impact on hypercholesterolemia-induced endothelial dysfunction. Methods and Results-Using human aortic ECs and bovine aortic ECs, we show that AMPK activation upregulates ATP binding cassette G1 (ABCG1) expression independently of liver X receptor alpha (LXR␣) transcriptional activity but through a posttranscriptional mechanism that increases mRNA stability. Using a heterologous system and a luciferase reporter, we further identify that the 3Ј-untranslated region of the ABCG1 mRNA is responsible for the regulatory effects of AMPK activation. 5-Aminoimidazole-4-carboxamide-1-␤-D-riboside treatment promotes endothelial 7-ketocholesterol efflux and prevents 7-ketocholesterol (7-KC)-induced reactive oxygen species production in an ABCG1-dependent manner, thus preserving endothelial nitric oxide synthase activity and nitric oxide bioavailability.
endothelial nitric oxide synthase (eNOS) activity and nitric oxide (NO) bioavailability, is a key feature of early atherosclerosis. [1] [2] [3] [4] A growing body of evidence has now implicated increased dietary oxysterols as a potent inhibitor of endothelium-dependent vascular relaxation and a significant contributor to the initiation and development of endothelial dysfunction, which suggests a vital link between hypercholesterolemia and the formation of atherosclerotic lesions. [5] [6] [7] Oxysterols are oxygenated forms of cholesterol that are present at low levels in the circulatory system and accumulate in plasma and tissues in some diseases. In characteristic lesions of atherosclerosis, 7-oxygenated oxysterols, predominantly 7-ketocholesterol (7-KC), are detectable at high levels and have been implicated in the pathology of this disease. 8, 9 Adenosine monophosphate activated protein kinase (AMPK) is a member of a metabolite-sensing protein kinase family, contains a catalytic ␣ subunit and regulatory ␤ and ␥ subunits, and functions as a protein serine/threonine kinase. 10 The activation of AMPK attenuates anabolic processes, such as the synthesis of proteins, fatty acids, and cholesterol, but stimulates ATP-generating catabolic pathways. 11 Recent findings further suggest that AMPK is also present in the endothelium and maintains endothelial homeostasis by regulating eNOS activity and increasing NO bioactivity. 12, 13 Hence, the bulk of the available data link AMPK signaling and endothelial function. However, the impact of AMPK activation on hypercholesterolemia-induced endothelial dysfunction and the involved underlying molecular mechanism remains unknown.
The ATP-binding cassette transporters ABCA1 and ABCG1 play an important role in inducing cellular cholesterol efflux 14 -16 and are known to be expressed in vascular endothelial cells (ECs). 17 More importantly, ABCG1 was recently shown to have a specific role not shared by ABCA1 in promoting the efflux of 7-oxysterols from ECs 18 and to markedly reverse hyperchoelsterolemia-induced endothelial dysfunction. 19 Because of the essential role of ABCG1 in regulating cholesterol homeostasis in vascular ECs, our present study was undertaken to test the hypothesis that AMPK, by promoting the ABCG1-mediated efflux of sterols and oxysterols from ECs, plays a key role in preserving eNOS activity and thus improving endothelial dysfunction in C57BL/6J mice exposed to a high-cholesterol diet (HCD). Our results show for the first time that ABCG1 is the critical mediator of the induction of cholesterol and 7-oxysterol efflux, of the preservation of NO bioavailability, and in the improvement of the hypercholesterolemia-induced endothelial dysfunction caused by AMPK.
Materials and Methods

Cell Culture
Human aortic ECs (HAECs) were cultured in M199 medium supplemented with FBS (20%), penicillin (100 U/mL), strepto-mycin (100 g/mL), heparin (90 g/mL), and EC growth supplement (20 g/mL). The cells were grown at 37°C in humidified 5% CO 2 and used for experiments between passages 3 and 5. For detailed methods, see the supplement, available online at http://atvb.ahajournals.org.
Results
AMPK Activation Upregulates ABCG1 Expression in Vascular ECs
To evaluate the effects of AMPK activation on ABCG1 expression, we exposed HAECs to the AMPK activator 5-aminoimidazole-4-carboxamide-1-␤-D-riboside (AICAR) (0 to 2 mmol/L) for 2 to 24 hours and examined the effects on ABCG1 expression. AICAR treatment was found to cause a time-dependent increase in the expression of ABCG1 mRNA as determined by Northern blot ( Figure 1A ) and quantitative RT-PCR ( Figure 1B ). The levels of ABCG1 mRNA, which reached a maximal 2.5-fold increased level over the control at 8 hours, were increased as early as 2 hours after the addition of AICAR to the cells. Moreover, the ABCG1 transcript levels remained high throughout the 24-hour treatment period. The effects of AICAR were found to be dose-dependent ( Figure 1C ). Northern blot analysis revealed a 50% increase in the ABCG1 mRNA levels in cells treated with The abundance of ABCG1 mRNA in untreated control cells was defined as 1, and the amounts of ABCG1 mRNA from AICAR-treated cells were then expressed as fold changes in this control value. *PϽ0.05, **PϽ0.01 versus 0 hours. C and D, Dosedependent induction of ABCG1 mRNA expression. HAECs were treated with AICAR for 8 hours at the indicated concentrations, and total RNA was isolated for the analysis of ABCG1 and GAPDH mRNA expression by Northern blot (C) and real-time polymerase chain reaction (D). *PϽ0.05, **PϽ0.01 versus 0 mmol/L. E, ABCG1 expression was measured by Western blot. F, The uptake of dioctadecylindocarbocyaniniodide (DiI)-HDL was measured by FACScan with 1ϫ10 5 cells per sample. The mean fluorescence intensity (MFI) of untreated cells is expressed as 100%. The data shown are expressed as a percentage of the control from 3 independent measurements. 0.25 mmol/L AICAR, and a maximal 4-fold increase over the control was seen with a concentration of 2 mmol/L. Increases of similar magnitudes in the ABCG1 mRNA levels could be confirmed by quantitative RT-PCR ( Figure 1D ). Western blot analysis also demonstrated that AICAR induces ABCG1 protein expression in a concentration-dependent fashion ( Figure 1E ).
Unrelated AMPK activators, such as metformin 20 and A-769662, 21 were also shown to increase ABCG1 mRNA and protein expression in HAECs (Supplemental Figure IA and IB). Furthermore, the overexpression of a constitutively active form of AMPK␣ (Ca-AMPK␣) led to a robust increase in ABCG1 expression that could not be further enhanced by AICAR. In contrast, when a dominantnegative form of AMPK␣ (Dn-AMPK␣) was overexpressed, AICAR was unable to enhance ABCG1 expression (Supplemental Figure IC) . The effects of AICAR on ABCG1 were further confirmed in bovine aortic ECs in which a similar increase in ABCG1 mRNA levels was observed (Supplemental Figure ID and IE). The enhancement of ABCG1 expression by AICAR was further found to directly translate into increased functional capacity, as it induced the binding of 3,3Ј-dioctadecylindocarbocyaniniodide-high-density lipoprotein (HDL) to HAECs in a dose-dependent manner ( Figure 1F ). This was almost completely abrogated following AMPK inhibition by compound C or Dn-AMPK␣ (Supplemental Figure IF) . The activation of AMPK thus triggers ABCG1 expression.
AMPK Activation Regulates ABCG1 mRNA Stability via Its 3-Untranslated Region
To elucidate the mechanism by which AMPK activation increases ABCG1 expression, we analyzed the impact of the AMPK agonist AICAR on LXR response element-dependent transcriptional activity by transfecting HAECs with an liver X receptor element (LXRE)-driven luciferase-reporter vector (LXRE-tk-Luc). Following transfection, cells were treated with vehicle or AICAR for 8 hours, but no effects on reporter activity could be detected (Figure 2A ). To further examine the mechanism by which AICAR increases ABCG1 expression, we analyzed ABCG1 promoter activity by transfecting HAECs with the reporter construct pABCG1Luc, after which the cells were treated with AICAR or GW3965. ABCG1 promoter activity was strongly elevated by GW3965, consistent with the findings of previous studies. However, AICAR had no effect on ABCG1 luciferase activity ( Figure 2B ). . AICAR increases ABCG1 expression by stabilizing its mRNA. A, HAECs were transfected with a luciferase reporter plasmid containing LXREs upstream of the thymidine kinase promoter (LXRE-tk-Luc) in the presence of ␤-galactosidase as a reference plasmid. Twelve hours after transfection, cells were treated with AICAR (0 to 2 mmol/L) for 24 hours. Luciferase and ␤-galactosidase activities were then determined in the cell lysates. The values represent the meanϮSEM relative to untreated cells (taken as 1) and are expressed as fold changes compared with the control values from 3 independent assays. B, pABCG1Luc and pRL-SV40 were cotransfected into HAECs cultured for 24 hours. AICAR (2 mmol/L) and GW3965 (1 mol/L) were added to the cells for 8 hours before cell lysis. The firefly luciferase and Renilla luciferase activities were then measured. The results are expressed as meanϮSEM and expressed as fold changes compared with the control values from 3 independent assays. *PϽ0.05 versus control. C, HAECs were untreated or treated with AICAR (1 mmol/L) for 24 hours, and actinomycin D (Act D; 5 g/mL) was added to the cells for different intervals. Total RNA was then isolated and ABCG1 mRNA was assayed by Northern blot. The normalized ABCG1 mRNA signals were plotted as the percentage of the ABCG1 mRNA remaining. D, Decay curves were plotted versus time. E, Ten hours after transfection with a pGL3 control vector and pGL3containing human ABCG1 3Ј-UTR, HAECs were treated with AICAR (1 mmol/L) or vehicle (control) for 24 hours. The cells were then lysed, and a luciferase assay was performed. The results from 3 independent experiments are presented as the meanϮSEM.
These results prompted us to then investigate the possibility that AICAR treatment may stabilize ABCG1 mRNA, resulting in higher expression levels. Actinomycin D was added to both vehicle-and AICAR-treated HAECs for specified periods, and the half-life of ABCG1 mRNA was determined by Northern blot in each case ( Figure 2C ). Based on the observed decay values, we found that AICAR prolongs the turnover rate of ABCG1 transcripts by approximately 3-fold (182 minutes versus 60 minutes; Figure 2D ). In contrast, the mRNA stability of GAPDH was unaltered by AICAR.
To further explore these stabilization mechanisms, we investigated whether AMPK modulates 3Ј-untranslated regions (3Ј-UTRs), which have been shown to destabilize mRNA. As shown in Figure 2E , the presence of the ABCG1 3Ј-UTR attenuates the baseline luciferase activity compared with an empty vector, and AICAR treatment restores this reporter activity. This indicates that the 3Ј-UTR of human ABCG1 plays a role in the mRNA stabilization induced by AMPK.
AMPK Activation Promotes Cholesterol and 7-KC Mass Efflux
We next investigated the role of AMPK activation in ABCG1-mediated cholesterol and 7-KC efflux. AICAR treatment induced both cholesterol and 7-KC mass efflux in a dose-dependent fashion in the presence of acceptor HDL ( Figure 3A ) which was significantly abolished by compound C or following Dn-AMPK␣ transfection ( Figure 3B ). This indicates an AMPK dependence of AICAR-stimulated cholesterol efflux. We next examined the effects of the knockdown of ABCG1 and ABCA1 by small interfering RNA (siRNA) transfection on AICAR-mediated cholesterol and 7-KC mass efflux. Western blot analysis revealed that ABCG1 and ABCA1 expression is effectively suppressed by siRNA (Supplemental Figure II) . The suppression of ABCG1 expression by the specific RNA interference (RNAi) significantly reduced both cholesterol and 7-KC mass efflux by AICAR, but ABCA1 silencing had no such effect ( Figure  3C ). These results indicate that ABCG1 is a critical regulator of the cholesterol and oxysterol efflux induced by AMPK activation.
AMPK Activation Modulates Oxidative Stress and Preserves eNOS Activity
To determine the consequences of AICAR-induced oxysterol efflux on oxidant stress, we measured 6-carboxy-2Ј-7Ј-dichlorodihydrofluorescein fluorescence, as this compound is a nonspecific marker of reactive oxygen species (ROS) accumulation. 22 Compared with vehicle-treated cells, cells ex- Figure  4A ), which were found to be associated with a concomitant decrease in the reduced glutathione to oxidized glutathione ratio ( Figure 4B ). Exposure to 7-KC also caused a significant decrease in eNOS activity ( Figure 4C ), whereas AICAR treatment reversed 7-KC mediated oxidative stress and eNOS disruption. We next examined the cGMP levels as a measure of the bioavailability of NO 23, 24 and found that they were markedly decreased in 7-KC-treated HAECs compared with the control cells. However, when stimulated with AICAR, 7-KC-treated cells demonstrated a significant increase in cGMP production ( Figure 4D ). ABCG1 suppression abrogated the ability of AICAR to protect against eNOS inhibition ( Figure 4C ) and reduction of NO bioavailability by 7-KC ( Figure 4D ), indicating the essential role of ABCG1 in the AICAR-mediated inhibition of oxidative stress and protection of eNOS activity.
AICAR Treatment Increases ABCG1 Expression, Reduces Cholesterol/7-KC Accumulation in the Aorta and Improves Endothelium-Dependent Vasorelaxation
To determine whether our in vitro findings could be reproduced in vivo, we treated normal cholesterol diet (NCD)-and HCD-fed C57BL/6J mice with AICAR or vehicle for 12 weeks. This treatment significantly increased the levels of phosphorylated AMPK Thr172 in the aorta compared with the control mice (Supplemental Figure IIIA) . AMPK activation by AICAR was also confirmed by AMPK activity analysis using the SAMS peptide as a substrate 25 (Supplemental Figure IIIB) . Simultaneously, AICAR treatment was found to markedly enhance ABCG1 protein expression in the aorta compared with untreated mice (Figure 5A and 5B) . We next measured the cholesterol and 7-KC contents in nonatherosclerotic thoracic and abdominal aortas, excluding the proximal aorta. Compared with NCD-fed mice, HCD-fed mice exhibited a more prominent accumulation of total cholesterol ( Figure 5C ) and 7-KC ( Figure 5D ) in the aorta, which was significantly decreased by AICAR treatment. We then analyzed the influence of oxysterol efflux on oxidative stress. Animals receiving AICAR displayed a significant reduction in superoxide radicals release compared with vehicle-treated littermates (Supplemental Figure IIIC) . In addition, aortic cGMP levels were significantly enhanced in AICAR-treated mice compared with vehicle-treated mice (Supplemental Figure IIID) .
We isolated ECs from aortas in HCD-fed mice. ABCG1 mRNA and protein expression in vascular ECs isolated from AICAR-treated mice were significantly increased compared with the vehicle-treated mice (Supplemental Figure IVA and IVB), and this was accompanied by a marked decrease in the total cholesterol mass (Supplemental Figure IVC) and 7-KC mass (Supplemental Figure IVD) in AICAR-treated mice. We further evaluated the vascular reactivity to examine the functional consequences of AMPK activation. Endotheliumdependent relaxation following exposure to acetylcholine (ACh) was markedly impaired in mice on HCD compared with mice on NCD. AICAR treatment also caused a striking improvement in aortic endothelium-dependent vasorelaxation in HCD-fed mice, indicative of a significant amelioration of endothelial dysfunction ( Figure 5E ). Endotheliumindependent relaxations following treatment with sodium nitroprusside were similar between the vehicle and AICAR-treated groups ( Figure 5F ). In addition, AICAR treatment did not alter the plasma lipid concentrations ( Supplemental Table I ). Hence, our findings suggest the possibility that the improvement in the vasodilatory responses in AICAR-treated mice may be brought about by a decreased aortic accumulation of cholesterol and 7-oxysterols.
AMPK Blockade or ABCG1 siRNA Gene Transfer Reverses Vascular Reactivity
To determine whether AMPK antagonists affect vascular reactivity in vivo, we treated HCD-fed C57BL/6J mice with AICAR in the presence or absence of the AMPK antagonist compound C. In AICAR-treated mice administered compound C, there was a significant decrease in ABCG1 expression (Supplemental Figure VA) and eNOS activity (Supplemental Figure VB) , accompanied by an increase in ROS (Supplemental Figure VC) and a decrease in the cGMP levels (Supplemental Figure VD) . Furthermore, in compound C-treated mice, the improved vasodilator responses to ACh by AICAR were reversed to levels observed in control mice (Supplemental Figure VE) .
To further determine the critical role of ABCG1 in the improvement of endothelial dysfunction mediated by AMPK, we suppressed ABCG1 expression using in vivo siRNA technology. In these experiments, wild-type mice were injected at the tail vein with 5ϫ10 9 plaque-forming units of Ad-ABCG1 siRNA or an empty control vector (Ad). AICARmediated upregulation of mouse aortic ABCG1 protein expression was found to be completely abrogated after infection with ABCG1 siRNA, compared with Ad ( Figure 6A ). Furthermore, in AICAR-treated mice, there was an increase in aortic ROS formation, as measured by lucigenin chemiluminescence, and a decrease in cGMP levels in Ad-ABCG1 siRNA-infected mice compared with Ad-infected mice (24.24Ϯ4.47 versus 51.62Ϯ2.41 relative light unit (RLU)/ second per mg of aorta, PϽ0.05, nϭ6; Figure 6B ) and (0.75Ϯ0.05 versus 0.39Ϯ0.05 pmol/mg protein, PϽ0.05, nϭ6; Figure 6C ), respectively. In addition, in AICAR-treated mice, vascular reactivity experiments revealed impaired vasodilation in response to ACh in Ad-ABCG1 siRNA-infected mice, an effect that was not observed in the Ad-infected mice ( Figure 6D ).
Discussion
The findings of our present study demonstrate for the first time that AMPK activation protects against hypercholester- olemia-induced endothelial dysfunction via the ABCG1mediated oxysterol efflux from vascular ECs. The following findings support this conclusion: (1) AMPK induces ABCG1 expression in ECs by regulating ABCG1 mRNA stability via its 3Ј-UTR; (2) at the cellular level, increased ABCG1 expression by AMPK activation promotes cholesterol and 7-KC efflux to HDL in ECs, causing a marked reduction in oxidative stress, the preservation of eNOS activity, and a concomitant increase in NO bioavailability; (3) in vivo experiments using HCD-fed C57BL/6J mice show that AICAR treatment increases vascular ABCG1 expression, reduces the cholesterol/7KC contents, decreases the ROS levels, and increases the cGMP levels, leading to a significant alleviation of vascular dysfunction; and (4) the protective effects of AICAR are lost in mice treated with the AMPK antagonist compound C or in those transfected with Ad-ABCG1 siRNA. Hence, our current data indicate that AMPK exerts its protective effects against endothelial dysfunction by inducing ABCG1 expression and thereby promoting cholesterol efflux from ECs.
ABCG1 is the best-characterized cholesterol transporter to date and has been shown to be expressed in vascular ECs. 26 In our current study, we demonstrate that AMPK activation by AICAR increases ABCG1 mRNA expression in a doseand time-dependent fashion in ECs. AICAR treatment was also found to increase ABCG1 protein expression, as well as upregulating the function of ABCG1 by increasing dioctadecylindocarbocyaniniodide-labeled HDL binding in vascular ECs. Previous studies that have addressed the role of AMPK may therefore have yielded equivocal results because of the unique role of AICAR as the means to increase AMPK activity. However, AICAR is regarded as a nonspecific AMPK activator and may affect other AMP-dependent enzymes. 27 In our present study, we used metformin and A-769662 as complementary methods of AMPK activation and found comparable effects of these agents on ABCG1 expression in ECs. Because the mechanism underlying metformin-and A-769662-mediated AMPK activation differs from that of AICAR, 21, 28 we are confident that our findings for the effects of AICAR are indeed due to AMPK activation. This contention is supported by our observations that both genetic and pharmacological approaches to block AICARmediated AMPK activation reverse the protective effects of AICAR in vitro and in vivo. To then examine the molecular mechanism by which AICAR regulates ABCG1 expression, we analyzed its impact on the LXR nuclear hormone receptor, which has been shown to be a critical regulator of ABCG1 expression. 29 However, we found that AICAR treatment does not stimulate the transcriptional activity of LXR in a reporter assay. AMPK also does not stimulate the transcription of ABCG1. Thus, posttranscriptional regulation appears to be the main mechanism underlying the effects of AMPK on endothelial ABCG1 expression. In the presence of the general inhibitor of gene transcription actinomycin D, we further found that the mRNA half-life of ABCG1 was considerably extended in AICAR-treated cells versus vehicle-treated HAECs. We thus sought to understand how AMPK affects the stability of ABCG1 transcripts by examining the ABCG1 mRNA 3Ј-UTR. Using Luc mRNA as the reporter, we found that the 3Ј-UTR of ABCG1 may indeed be involved in posttranscriptional regulation by AMPK.
ABCG1 is a member of the ATP binding cassette transporter family, and its role in regulating cholesterol homeostasis in macrophages and ECs has been investigated by several groups. 18,30 -32 In view of the critical role of ABCG1 in mediating cholesterol efflux, we further studied the impact of AICAR on ABCG1 function by analyzing the efflux of oxysterols from ECs. We found that AICAR exposure in- Figure 6 . ABCG1 inhibition abolishes the impact of vascular reactivity by AICAR. A, Two groups of C57BL/6J mice received a high-fat, cholesterol-rich diet (HCD) for 12 weeks. The animals were also randomly administered either AICAR (200 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 ) or vehicle (0.9% NaCl). During the final 2 weeks of the 12-week treatment period, the vehicleand AICAR-treated mice were injected at the tail vein with 5ϫ10 9 plaque-forming units of a recombinant adenovirus containing mouse ABCG1 siRNA under the control of the cytomegalovirus promoter (Ad-ABCG1 siRNA, nϭ6) or an empty viral vector (Ad, nϭ6) , respectively. The animals were subsequently euthanized, and the aortas were excised for analysis. A, At 14 days posttransfection, ABCG1 protein expression was measured by Western blot. B, The aorta superoxide levels were determined by lucigenin chemiluminescence. C, cGMP levels were measured as the indicator of the levels of bioavailable NO. D, Endothelial relaxation was assessed by vascular reactivity to increasing concentrations of ACh. Data represent the meanϮSEM; nϭ6 per group. *PϽ0.05.
duced total cholesterol and 7-KC mass efflux from HAECs and that this was significantly diminished by ABCG1 siRNA. ABCA1, another member of the ATP-binding cassette transporter family, has also been shown to mediate cholesterol and phospholipid efflux to lipid-poor apolipoprotein A-I and could be detected on ECs. 17 However, incubation with ABCA1 siRNA did not affect the sterol efflux induced by AICAR. These results indicate that ABCG1 is necessary to promote the efflux of 7-KC from HAECs induced by AICAR.
The key marker of vascular integrity and endothelial function is the preserved bioavailability of NO, which is regulated by eNOS activity. The NO pathway is impaired in hypercholesterolemia after the breakdown of NO for its reaction with O 2 Ϫ , which is known to inactivate NO and generate ONOO Ϫ . 33, 34 Our current data indicate that the profound improvements in endothelial function induced by AICAR are associated with the upregulation of aortic eNOS activity, leading to enhanced cGMP production. At the same time, we observed a marked decrease in aortic superoxide levels, assessed by L-012 chemiluminescence and dihydroethidium (DHE) staining, in AICAR-treated mice compared with vehicle-treated mice. Hence, it appears that the modulation of eNOS activity by AICAR treatment results in increased NO bioavailability and decreased superoxide production, consistent with the observed improvement in endothelial-dependent vasorelaxation.
Recently, Terasaka et al 19 have reported that ABCG1 maintains EC function in HCD-fed mice by promoting the efflux of cholesterol and 7-oxysterols, thus highlighting an important role for ABCG1 in preserving endothelial function. However, whether the amelioration of hypercholesterolemiamediated vascular impairment by AICAR is related to ABCG1 has not yet been explored. To further substantiate our present in vitro findings by in vivo analyses, we examined the effects of AICAR administration on HCD-fed C57BL/6J mice. Notably, we observed that ABCG1 expression is significantly enhanced in aortas from AICAR-treated mice compared with vehicle-treated mice. In accordance with these findings, the total cholesterol (mainly 7-KC) accumulation in aortas was found to be markedly decreased by AICAR treatment compared with vehicle-treated mice. Our studies have thus uncovered a novel mechanism whereby AMPK activation may be involved in an increased efflux of cholesterol and 7-oxysterols via the ABCG1 pathway, thus enhancing eNOS activity and NO bioavailability. Our present data thus complement important earlier observations and suggest that the underlying mechanism by which increased AMPK activation via AICAR protects the endothelium involves the efflux of dietary sterols, particularly 7-oxysterols, from ECs to HDL. This is principally mediated in mice by ABCG1. More detailed analysis shows that ABCG1 expression in the endothelium is significantly increased, mainly in vascular EC fractions, after AICAR treatment. The improvements in endothelium-dependent vasodilatation occur in the absence of blood lipid lowering by AICAR and are thus possibly associated with a significant reduction in 7-KC accumulation but an increase in ABCG1 expression in the aorta despite persistent severe hypercholesterolemia.
Taken together, our current findings suggest that AMPK activation prevents hypercholesterolemia-mediated endothelial dysfunction and that the underlying mechanism may involve an increased efflux of cholesterol and 7-oxysterols via the ABCG1 pathway. We thus provide evidence that AMPK is potentially a critical target for the future treatment of endothelial dysfunction in vascular disease.
